AxoGen (NASDAQ:AXGN) Rating Lowered to Hold at StockNews.com

AxoGen (NASDAQ:AXGN) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $12.00 price objective on shares of AxoGen in a report on Friday, January 19th.

AxoGen Price Performance

Shares of AXGN opened at $5.83 on Monday. AxoGen has a 52-week low of $3.45 and a 52-week high of $10.83. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.23 and a current ratio of 3.43. The business’s 50 day moving average price is $7.66 and its two-hundred day moving average price is $7.50. The firm has a market cap of $254.83 million, a PE ratio of -11.66 and a beta of 1.07.

AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Tuesday, March 5th. The medical equipment provider reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.11. The firm had revenue of $42.92 million during the quarter, compared to the consensus estimate of $42.70 million. AxoGen had a negative return on equity of 22.18% and a negative net margin of 12.99%. On average, equities analysts anticipate that AxoGen will post -0.46 EPS for the current year.

Insider Buying and Selling

In related news, insider Erick Wayne Devinney sold 4,578 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $35,159.04. Following the completion of the sale, the insider now owns 165,661 shares in the company, valued at $1,272,276.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, insider Erick Wayne Devinney sold 4,578 shares of the company’s stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $7.68, for a total transaction of $35,159.04. Following the completion of the sale, the insider now owns 165,661 shares in the company, valued at $1,272,276.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gregory Gene Freitag sold 25,000 shares of the company’s stock in a transaction on Thursday, March 7th. The stock was sold at an average price of $9.00, for a total value of $225,000.00. Following the sale, the director now owns 271,594 shares of the company’s stock, valued at approximately $2,444,346. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 111,201 shares of company stock worth $928,054. 7.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On AxoGen

Several institutional investors have recently bought and sold shares of AXGN. Nisa Investment Advisors LLC grew its stake in AxoGen by 534.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 7,805 shares of the medical equipment provider’s stock valued at $53,000 after purchasing an additional 6,575 shares during the period. SG Americas Securities LLC bought a new position in AxoGen in the 3rd quarter valued at $51,000. Eagle Asset Management Inc. bought a new position in AxoGen in the 3rd quarter valued at $63,000. Sherbrooke Park Advisers LLC bought a new position in AxoGen in the 3rd quarter valued at $83,000. Finally, Sentry Investment Management LLC bought a new position in AxoGen in the 4th quarter valued at $131,000. Institutional investors own 80.29% of the company’s stock.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.